You are here: Industry Insights > nAMD

News List

FDA accepts application for Roche’s Faricimab expresspharma
July 30, 2021
If approved, Faricimab would be the first and only medicine designed to target two distinct pathways that drive retinal diseases that can cause vision loss.
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular prnasia
April 29, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the ...
Patients Win When Support Is Personalized: New Study From Atlantis Healthcare Shows Treatment Persistence and Adherence Improved by 38% prnasia
March 08, 2021
Leading patient outcomes journal Patient Preference and Adherence has published a study that demonstrates significant improvement in treatment behaviors among patients with neovascular age-related macular degeneration (nAMD) who received personalized ...
Roche’s vision loss therapy faricimab extends time between treatments by up to four months pharmatimes
February 20, 2021
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Roche’s faricimab hits primary endpoint in wet AMD studies pharmatimes
January 27, 2021
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Relat prnasia
November 16, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of the ...